Pfizer RSV Vaccine Approval

News

Pfizer gets ACIP backing

Pfizer gets ACIP backing as it votes to expand RSV vaccine recommendation

The U.S. Centers for Disease Control and Prevention’s vaccine panel voted to expand its recommendation for the use of respiratory syncytial virus (RSV) shots in adults with 50-59 years of age at increased risk of RSV-associated lower respiratory tract disease,

STAT · 3d

Vaccine advisory panel recommends expanded RSV use, and two new vaccines

The Advisory Committee on Immunization Practices voted Wednesday to recommend lowering the age at which adults can get a vaccine against respiratory syncytial virus.

Yahoo Finance · 2d

US Advisory Panel Votes To Expand Recommendation For Pfizer, GSK's RSV Vaccines For Older Adults Below 60 Years

On Wednesday, the Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of respiratory syncytial virus (RSV) vaccines approved for adults 50-59 years of age at increased risk of RSV-associated lower respiratory tract disease (LRTD).

Fierce Pharma3d

RSV shots from GSK, Pfizer get potential boost from broadened ACIP guidance

A year after narrowing its recommendation for who should use vaccines to defend against respiratory syncytial virus (RSV), a ...

Morningstar4d

ACIP Votes to Expand Recommendation for Pfizer’s RSV Vaccine ABRYSVO® to Include Adults Aged 50 to 59 at Increased Risk of Disease

is pending final approval by the director of the CDC and the Department of Health and Human Services. Pfizer currently is the only company with an RSV vaccine to help protect adults aged 60 ...

pharmaphorum3d

There's good news for RSV jab firms at delayed ACIP meeting

The Advisory Committee on Immunisation Practices (ACIP) has voted to widen the recommendations on the use of RSV shots to ...

ACIP votes to expand recommendation for Pfizer’s RSV vaccine

Pfizer (PFE) announced that the U.S. Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand ...

4don MSN

Single-dose vaccine demonstrates sustained efficacy against RSV-related lower respiratory tract disease in older adults

Researchers from GlaxoSmithKline have reported that a single dose of the RSV vaccine, Arexvy (RSVPreF3 OA), provides ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results